RNS & Investor News
Launch of SlimBiome® in North America with Agropur Inc.
31 January 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, and Agropur Inc. ("Agropur") have announced the launch of SlimBiome in the North American market. This launch follows the announcement (RNS: 24 June 2019) that OptiBiotix granted Agropur an exclusive license to manufacture, supply and distribute OptiBiotix's SlimBiome® weight management technology in the USA, Canada and Mexico.
Agropur is a wholly owned subsidiary of Agropur Cooperative, which is a North American dairy industry leader founded in 1938. With 8,800 employees and sales of US$5.5 billion in 2019, Agropur processes more than 14 billion lbs of milk per year at its 38 plants across North America.
Mike Homewood, Vice President of Agropur Custom Solutions, said, "We are proud of our agreement and partnership with OptiBiotix and the exclusive opportunity to bring SlimBiome® to the North American food and nutrition industries. This ingredient solution for weight management fits into Agropur's goal to provide innovative, forward-thinking products to our customers."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented, "We are very pleased with the progress Agropur has made since the announcement of our partnership at the end of June 2019. Over a rather short period of time, Agropur has qualified its manufacturing process and is now able to produce SlimBiome® in the USA and supply the ingredient to North American B2B customers. This is a key strategic step In OptiBiotix's commercial development as it grants the company access to the US weight management market which was estimated to be worth US$72 billion in 2019 (source: BusinessWire.com)."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O’Hara, Chief Executive
Contact via Walbrook below
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
|goetzpartners securities Limited||Tel: 0203 859 7725|
|Walbrook PR Ltd
|Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Optibiotix Health makes strong start to 2020 with new product launches and agreements
Stephen O'Hara | 14 Feb 2020